Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a commercial-stage biopharmaceutical company whose news flow centers on cancer drug development, regulatory milestones, and commercialization updates. The company’s announcements emphasize progress with its two FDA-approved therapies: Revuforj® (revumenib), an oral menin inhibitor for specific relapsed or refractory acute leukemias, and Niktimvo™ (axatilimab-csfr), a CSF-1 receptor-blocking antibody for chronic graft-versus-host disease after at least two prior systemic therapies.
News for SNDX often covers quarterly and annual financial results, product revenue trends for Revuforj and Niktimvo, and guidance on research and development as well as selling, general and administrative expenses. Investors can follow updates on clinical trial milestones, such as Phase 2 and Phase 3 studies of revumenib in newly diagnosed and relapsed or refractory NPM1-mutated and KMT2A-rearranged AML, and trials of axatilimab in chronic GVHD and idiopathic pulmonary fibrosis.
Press releases also highlight regulatory events, including FDA approvals and label expansions, inclusion of revumenib in clinical practice guidelines, and special designations such as Orphan Drug, Fast Track, and Breakthrough Therapy. Scientific and medical conference activity is another recurring theme, with multiple abstracts and oral presentations at meetings like the American Society of Hematology and appearances at investor conferences and healthcare forums.
In addition, Syndax issues news on collaborations and access initiatives, such as its agreement with the World Orphan Drug Alliance to launch a multi-regional Managed Access Program for Revuforj outside the United States. For investors and observers tracking SNDX, the news stream provides insight into commercial performance, pipeline evolution, partnership activity, and the company’s stated path toward profitability.
Syndax Pharmaceuticals announced it will release its third quarter 2020 financial results on November 2, 2020, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the live event via the company's website. Syndax develops innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat, aiming to improve treatment options. For more details, visit www.syndax.com.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced participation in three upcoming virtual investor conferences. The events include the Citi 15th Annual BioPharma Virtual Conference on September 9, 2020, a panel at 11:40 a.m. ET, the Baird 2020 Virtual Global Healthcare Conference on September 10, 2020, with a fireside chat at 4:20 p.m. ET, and the Morgan Stanley 18th Annual Global Virtual Healthcare Conference on September 14, 2020, with a fireside chat at 2:15 p.m. ET. Live webcasts will be available on the company’s website, with a replay following the events.
Syndax Pharmaceuticals (SNDX) reported its Q2 2020 financial results, revealing a net loss of $17.1 million, or $0.42 per share, compared to $14.9 million, or $0.47 per share, in Q2 2019. The company is focused on advancing its pipeline, particularly SNDX-5613, for which the FDA approved key changes to its AUGMENT-101 trial, now targeting pediatric and specific leukemia patients. Research and development expenses decreased to $10.9 million in Q2 2020. Syndax projects operating expenses of $40 to $45 million for the second half of 2020, emphasizing continuous commitment to improving cancer treatments.
Syndax Pharmaceuticals (Nasdaq:SNDX) announced participation in the BTIG Biotechnology Conference on August 10, 2020, at 12:00 p.m. ET. The company's management team will engage in a virtual fireside chat, and a live webcast will be available on its investor website, with a replay accessible temporarily. Syndax is focused on developing innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat. For further details, visit www.syndax.com.
Syndax Pharmaceuticals will release its Q2 2020 financial results on August 6, 2020, after U.S. market close. The management team will hold a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update. Investors can access the webcast on the company's website. Syndax is developing a pipeline of cancer therapies, including drug candidates SNDX-5613, axatilimab, and entinostat.
Syndax Pharmaceuticals has appointed Daphne Karydas as Chief Financial Officer, effective July 13, 2020. Karydas has nearly 20 years of experience in the biopharmaceutical sector, serving most recently at Allergan. She replaces Richard P. Shea, who is retiring. CEO Briggs W. Morrison expressed confidence in Karydas’ ability to drive long-term growth as the company advances key drug programs, including SNDX-5613 and axatilimab, with critical readouts expected in Q4 2020. Karydas aims to leverage her expertise to improve patient outcomes in cancer care.